Advanced Search
Users Online: 158
Home
About us
Editorial board
Ahead of print
Current Articles
Search
Archives
Submit article
Instructions
Subscribe
Contacts
Reader Login
Export selected to
Endnote
Reference Manager
Procite
Medlars Format
RefWorks Format
BibTex Format
Most cited articles *
Archives
Most popular articles
Most cited articles
Show all abstracts
Show selected abstracts
Export selected to
Cited
Viewed
PDF
REVIEW ARTICLES
Using Clinical Decision Support Systems for Acute Kidney Injury Pragmatic Trials
Kianoush Kashani, Nooshin Dalili, Rickey E Carter, John A Kellum, Ravindra L Mehta
2019, 1:28 (3 January 2019)
DOI
:10.4103/jtccm.jtccm_6_18
Following the initial introduction of clinical decision support systems (CDSS) into the clinical practice in the 1970s, the complexity and performance quality of CDSSs have increased. The current literature on the efficacy and effectiveness of such systems shows conflicting results. While some studies show a clear benefit in quality-of-care improvement, others fail to replicate these outcomes. Heterogeneity of studies and the complexity of CDSS characteristics drive these conflicting conclusions. The lower cost and the easier implementation of pragmatic clinical trials provide an excellent platform to prove the effectiveness of CDSS in the real-world scenarios. To achieve better results, a series of explanatory trials are needed to identify the most effective CDSS in controlled settings. Therefore, utilization of both explanatory and pragmatic trial designs is necessary to evaluate the safety and efficacy of CDSS on the care of patients with acute kidney injury (AKI) in the acute setting. In this review, the authors provide an overview of the literature on critical care-related CDSS, its characteristics and dimensions, differences between pragmatic and explanatory trials, and potential proposals for both trial designs for AKI.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
2
3,278
328
EDITORIAL
Editorial - Focus on the Study of Coronavirus Disease 2019
Yuan Zhu, Zhiyong Peng
2020, 1:75 (28 October 2020)
DOI
:10.4103/jtccm.jtccm_17_20
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
1
1,661
154
LETTERS TO THE EDITOR
D Vitamin, Coronavirus, and Neurological Injuries
William Andres Florez Perdomo, Harold Enrique Vásquez Ucros, Luis Rafael Moscote-Salazar
2020, 2:64 (31 December 2020)
DOI
:10.4103/jtccm.jtccm_5_20
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
1
3,885
134
REVIEW ARTICLE
Galectin-3 and Fibrosis: Research in the Last 5 Years
Isaac Eliaz
2020, 1:117 (31 December 2020)
DOI
:10.4103/jtccm.jtccm_15_19
Tissue fibrosis is initially an adaptive response to organ injury, but eventually, parenchymal scarring and subsequent cellular dysfunction and organ failure ensue. Few therapies currently exist for fibrosis, especially those that target fibrogenesis. Galectin-3 (Gal-3) is a member of the lectin family of proteins, is produced predominantly by macrophages, and has essential functions in inflammation and angiogenesis. Gal-3 is activated in fibrotic models and abnormally elevated in fibrotic patients. Gal-3 inhibitors help to ameliorate or prevent fibrosis. For this review, we searched for original articles and reviews published between Jul 1, 2014, and Nov 1, 2019, using the following search terms (or combination of words) in PubMed: “galectin 3”, “fibrosis”, “heart”, “cardiac”, “liver”, “hepatic”, “lung”, “pulmonary”, “kidney”, and “renal”.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
1
1,568
114
REVIEW ARTICLES
Desmopressin in Critically Ill Neurosurgical Patients: An Overview
Angie Ching-Gonzalez, Christian Meza-Valle, Karen Muñoz-Báez, Juan Medrano-Carreazo, Amit Agrawal, Rakesh Mishra, Adesh Shrivastava, Tariq Janjua, Luis Rafael Moscote-Salazar
2020, 2:23 (31 December 2020)
DOI
:10.4103/jtccm.jtccm_14_20
Severely ill neurosurgical patients are those who present with pathologies of the nervous system associated with either a high mortality or that which leaves significant sequelae in those who survive. Desmopressin is a synthetic analog of the antidiuretic hormone that is stored in neurohypophysis. Its function is to decrease urinary volume by increasing reabsorption of water in the convoluted tubules and nephron collectors, additionally increasing the expression of coagulation factor VII and the von Willebrand factor. For this reason, its usefulness in the management of various pathologies has been tested, from coagulopathies to posttraumatic and postsurgical diabetes insipidus. It contributes in improving hyponatremia and in maintaining the balance of fluids and electrolytes in traumatic brain injury and subarachnoid hemorrhage (SAH) patients. It has been additionally studied for its role in the risk of rebleeding in SAH patients and in those with coagulopathies, where its implicated mechanism of action is through platelet anti-aggregation.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
1
1,997
148
The Short- and Long-Term Burden of Acute Kidney Injury
Jonah G Powell-Tuck, Jorge Cerda, Marlies Ostermann
2019, 1:35 (3 January 2019)
DOI
:10.4103/jtccm.jtccm_7_18
Acute kidney injury (AKI) is a common complication of acute illness and carries a significant risk of mortality and morbidity, resulting in high health-care-associated costs. The incidence of AKI appears to be rising, making it ever more important to understand its acute and chronic consequences. In this review, we explore the evolving epidemiology of AKI, describe the impact of AKI on other organs, and discuss the short- and long-term effects of AKI on mortality and morbidity and its economic burden.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
1
3,162
323
Angiotensin in Clinical Practice
Ehsan Ahmadnia, Anna Hall, Marlies Ostermann
2019, 1:7 (3 January 2019)
DOI
:10.4103/jtccm.jtccm_1_18
Interest in the use of angiotensin (AT) (particularly in the context of shock) had been rekindled by recent randomized trial data (notably the AT II for the Treatment of High-Output Shock-3 study). This review article outlines the renin–AT system in health and during sepsis as well as the proposed clinical uses of AT II. The potential for wider application within critical care is also considered.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
[CITATIONS]
1
4,967
397
* Source: CrossRef
Sitemap
|
What's New
|
Feedback
|
Disclaimer
|
Privacy Notice
© Scholar Media Publishing Co. Ltd | Published by Wolters Kluwer -
Medknow
Online since 24
th
Dec, 2014